Register Login

New Antiplatelet Drug in Phase 2

This message remained in draft form in our prior Fritsma Factor site, which was discontinued yesterday, Tuesday, November 1. We will be posting more about the development of this therapeutic. describes a new antiplatelet drug by Schering-Plough that targets the PAR-1 platelet membrane receptor. This is the thrombin receptor, and the study supports that platelets are suppressed with reduced bleeding risk.

Comments (0)

No comments here.

Leave a Reply